Introduction

Zika virus is primarily transmitted by infected mosquitoes of the Aedes (Stegomyia) genus, mainly Aedes aegypti, in tropical and subtropical regions. Aedes mosquitoes usually bite during the day. It is also transmitted from mother to fetus during pregnancy, as well as through sexual contact, transfusion of blood and blood products, and possibly through organ transplantation.

Most people with ZIKV infection do not develop symptoms, those who do typically have symptoms including rash, fever, conjunctivitis, muscle and joint pain, malaise and headache that last for 2–7 days. ZIKV infection during pregnancy can cause infants to be born with microcephaly and other congenital malformations as well as preterm birth and miscarriage. It's infection is associated with Guillain-Barré syndrome, neuropathy and myelitis in adults and children.

In February 2016, WHO declared Zika-related microcephaly a Public Health Emergency of International Concern (PHEIC), and the causal link between the ZIKV and congenital malformations was confirmed. WHO declared the end of the PHEIC in November of the same year. Although cases of ZIKV disease declined from 2017 onwards globally, transmission persists at low levels in several countries in the Americas and other endemic regions.

This kit is designed with specific primers and probes targeting the conserved region of ZIKV, generating fluorescence signals on a constant temperature nucleic acid amplification instrument. By employing POCT detection, it realizes qualitative and genotypic identification of ZIKV at the nucleic acid level.